• CG Oncology named Isabel Kalofonos as chief commercial officer as it prepares for a potential launch of cretostimogene grenadenorepvec.
• Kalofonos previously served as chief commercial officer at Crinetics Pharmaceuticals, supporting the launch of PALSONIFY (paltusotine) before its sale to Vertex.
• She earlier held chief commercial officer roles at ImmunoGen, leading the launch of ELAHERE, with prior senior commercial posts at Galderma, Takeda, and Shire.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130800PRIMZONEFULLFEED9844330) on October 13, 2026, and is solely responsible for the information contained therein.